BCGF
MCID: BCL014
MIFTS: 43

B-Cell Growth Factor (BCGF)

Aliases & Classifications for B-Cell Growth Factor

MalaCards integrated aliases for B-Cell Growth Factor:

Name: B-Cell Growth Factor 58
B-Cell Growth Factor 1; Bcgf1 58
B-Cell Growth Factor 1 58
Bcgf1 58
Bcgf 58

External Ids:

OMIM 58 109540

Summaries for B-Cell Growth Factor

MalaCards based summary : B-Cell Growth Factor, also known as b-cell growth factor 1; bcgf1, is related to systemic lupus erythematosus and autoimmune disease. An important gene associated with B-Cell Growth Factor is TXLNA (Taxilin Alpha), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Metronidazole and Ciprofloxacin have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and lung.

Description from OMIM: 109540

Related Diseases for B-Cell Growth Factor

Diseases related to B-Cell Growth Factor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 29.4 IFNG IL4 IL6 TNFSF13
2 autoimmune disease 29.3 IFNG IL4 IL6
3 common variable immunodeficiency 28.9 TNFSF13 IL6 IL4 IFNG
4 rheumatoid arthritis 28.9 IFNG IL4 IL6 TNFSF13
5 pediatric systemic lupus erythematosus 10.9
6 leukemia 10.4
7 lymphocytic leukemia 10.3
8 lupus erythematosus 10.2
9 hyperlucent lung 10.2 IFNG IL4
10 severe combined immunodeficiency, x-linked 10.2 IL4 IL7
11 nickel allergic contact dermatitis 10.2 IFNG IL4
12 allergic contact dermatitis 10.2 IFNG IL4
13 baylisascariasis 10.2 IFNG IL4
14 penicillin allergy 10.2 IFNG IL4
15 scleritis 10.2 IFNG IL4
16 crustacean allergy 10.2 IFNG IL4
17 toxic oil syndrome 10.2 IFNG IL4
18 urinary schistosomiasis 10.2 IFNG IL4
19 schistosomiasis 10.2 IFNG IL4
20 folliculitis 10.2 IFNG IL4
21 hyper ige syndrome 10.2 IFNG IL4
22 orofacial granulomatosis 10.2 IFNG IL4
23 buruli ulcer 10.2 IFNG IL4
24 primary systemic mycosis 10.2 IFNG IL4
25 poliomyelitis 10.2 IFNG IL4
26 lichen disease 10.2 IFNG IL4
27 coccidiosis 10.2 IFNG IL4
28 leukemia, chronic lymphocytic 2 10.2
29 leukemia, chronic lymphocytic 10.2
30 lymphoma 10.2
31 leukemia, b-cell, chronic 10.2
32 cryptococcosis 10.2 IFNG IL4
33 vernal conjunctivitis 10.2 IFNG IL4
34 paranasal sinus disease 10.2 IFNG IL4
35 acute graft versus host disease 10.2 IFNG IL4
36 allergic conjunctivitis 10.1 IFNG IL4
37 autoimmune uveitis 10.1 IFNG IL4
38 opportunistic mycosis 10.1 IFNG IL4
39 intrinsic asthma 10.1 IL3 IL4
40 eosinophilic gastritis 10.1 IL3 IL4
41 b-cell lymphomas 10.1
42 ige responsiveness, atopic 10.1 IFNG IL4
43 neuritis 10.1 IFNG IL4
44 food allergy 10.1 IFNG IL4
45 cyclic neutropenia 10.1 IFNG IL3
46 respiratory allergy 10.1 IL3 IL4
47 leukemia, acute lymphoblastic 10.1
48 cutaneous leishmaniasis 10.0 IFNG IL4
49 autoimmune gastritis 10.0 IL4 IL6
50 acute monoblastic leukemia 10.0 IL6 IL7

Graphical network of the top 20 diseases related to B-Cell Growth Factor:



Diseases related to B-Cell Growth Factor

Symptoms & Phenotypes for B-Cell Growth Factor

Clinical features from OMIM:

109540

Drugs & Therapeutics for B-Cell Growth Factor

Drugs for B-Cell Growth Factor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 224)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metronidazole Approved Phase 4 443-48-1 4173
2
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
3
Vancomycin Approved Phase 4 1404-90-6 441141 14969
4
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 637568 5271565
5 Adjuvants, Immunologic Phase 4,Phase 2,Phase 1,Not Applicable
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Interleukin-4 Phase 4,Phase 2,Phase 1,Not Applicable
11 Immunosuppressive Agents Phase 4,Phase 1,Phase 2
12 Anti-Infective Agents Phase 4,Phase 1,Phase 2,Not Applicable
13 Broncho-Vaxom Phase 4
14 Brewer's Yeast Phase 4
15 Interleukin-12 Phase 4
16 Mitogens Phase 4,Phase 1,Phase 2
17 Antiprotozoal Agents Phase 4
18 Complement System Proteins Phase 4,Not Applicable
19 Antiparasitic Agents Phase 4
20 Topoisomerase Inhibitors Phase 4
21 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2
22 Antitubercular Agents Phase 4,Phase 1,Phase 2
23 Complement Inactivating Agents Phase 4
24 Complement C1 Inhibitor Protein Phase 4
25 Complement C1 Inactivator Proteins Phase 4
26 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
27 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2
28 Cytochrome P-450 Enzyme Inhibitors Phase 4
29 Caseins Phase 4,Not Applicable
30 Dermatologic Agents Phase 4,Phase 1,Phase 2
31
Dexmedetomidine Approved, Vet_approved Phase 2, Phase 3 113775-47-6 68602 5311068
32
Histamine Approved, Investigational Phase 2, Phase 3,Phase 1 51-45-6 774
33
Methylcobalamin Approved, Experimental, Investigational Phase 2, Phase 3,Not Applicable 13422-55-4
34
Hydroxocobalamin Approved Phase 2, Phase 3,Not Applicable 13422-51-0 11953898 15589840
35
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59-30-3 6037
37
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3,Not Applicable 68-19-9 44176380
38
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3 65-23-6 1054
39
Cobalamin Experimental Phase 2, Phase 3,Not Applicable 13408-78-1 6857388
40 Analgesics, Non-Narcotic Phase 2, Phase 3,Phase 1,Not Applicable
41 Hypnotics and Sedatives Phase 2, Phase 3,Phase 1
42 Adrenergic alpha-Agonists Phase 2, Phase 3
43 Adrenergic Agents Phase 2, Phase 3,Not Applicable
44 Analgesics Phase 2, Phase 3,Phase 1,Not Applicable
45 Central Nervous System Depressants Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
46 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 1,Not Applicable
47 Anesthetics Phase 2, Phase 3,Phase 1
48 Adrenergic alpha-2 Receptor Agonists Phase 2, Phase 3
49 Neurotransmitter Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
50 Adrenergic Agonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections Completed NCT00599417 Phase 4 Bacterial Lysates;placebo
2 Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C:An Open-label Control Study in China Completed NCT02898922 Phase 4
3 Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen Completed NCT02690935 Phase 4 2LALERG;Placebo
4 C1-inhibitor in Allergic ASThma Patients Recruiting NCT03051698 Phase 4 C1-inhibitor;Antibiotics
5 A1 Versus A2® Milk on the Gastrointestinal Physiology, Symptoms and Cognitive Behaviour for the Preschool Children Completed NCT03081845 Phase 4
6 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
7 Immune Effect of Dexmedetomidine in Patients Undergoing to Spinal Fusion Unknown status NCT02854904 Phase 2, Phase 3 Dexmedetomidine intervention;Placebo
8 Intravenous Immunoglobulins in Complex-regional Pain Syndrome Unknown status NCT00949065 Phase 3
9 Stopping Postpartum Vitamin A Supplementation: Missing Concealed Benefit Completed NCT02043223 Phase 2, Phase 3
10 A Human Trial to Evaluate the Effects of Chungkookjang on Histamine-induced Wheal Size in Healthy Subjects Completed NCT01402141 Phase 2, Phase 3
11 Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT) Completed NCT00833898 Phase 3
12 A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs Completed NCT00996606 Phase 3 DMARDs;Tocilizumab
13 Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Not yet recruiting NCT03790345 Phase 2, Phase 3 Pyridoxine;Cobalamin;Placebo Oral Tablet
14 Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia Recruiting NCT03788759 Phase 2, Phase 3 Alpha-lipoic acid;Placebo Oral Tablet
15 Sinupret Extract Coated Tablets in Chronic Rhinosinusitis Completed NCT02746042 Phase 3 Sinupret extract coated tablets;Placebo coated tablets
16 Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis Unknown status NCT01638520 Phase 2 Pascolizumab;Placebo
17 Effectiveness of an Individualized Program of Muscular Strength and Endurance Program for Improving Germ Cell Cancer Unknown status NCT02433197 Phase 1, Phase 2
18 Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure Unknown status NCT01844063 Phase 1, Phase 2 Conventional treatment
19 Recombinant Human IL-4 Receptor Used in Treatment of Asthma Completed NCT00017693 Phase 2
20 Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma Completed NCT00001909 Phase 2 Soluble recombinantly produced IL-4R
21 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma Recruiting NCT02858895 Phase 2 MDNA55
22 NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme Completed NCT00014677 Phase 2
23 Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer Terminated NCT00776295 Phase 2
24 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Completed NCT00923910 Phase 1, Phase 2 WT1 Peptide-Pulsed Dendritic Cells;Donor Lymphocytes;IL-4;KLH;WT1 Peptides;Endotoxin;Diphenhydramine;Acetaminophen
25 Study to Determine the Safety and Effectiveness of Dupilumab (REGN668/SAR231893) for Treatment of Atopic Dermatitis (AD) Completed NCT01979016 Phase 2 dupilumab;placebo
26 Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) Terminated NCT01212094 Phase 1, Phase 2 Rituximab
27 Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma Terminated NCT00006113 Phase 2
28 A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age Recruiting NCT03303625 Phase 1, Phase 2 Placebo
29 Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics Completed NCT00535431 Phase 2 AER 001;placebo
30 A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study) Completed NCT00535028 Phase 2 AER 001;placebo
31 Atacicept in Multiple Sclerosis Extension Study, Phase II Terminated NCT00853762 Phase 2 Atacicept 25 mg;Atacicept 75 mg;Atacicept 150 mg;Atacicept 150 mg
32 Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease Active, not recruiting NCT02611167 Phase 1, Phase 2
33 Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy Terminated NCT00534209 Phase 1, Phase 2
34 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis Completed NCT02776033 Phase 2 GSK2982772;Placebo
35 Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy Completed NCT01739777 Phase 1, Phase 2
36 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
37 Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65. Completed NCT03167593 Phase 2
38 IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma Unknown status NCT00003842 Phase 1 isolated perfusion
39 A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma Completed NCT00000769 Phase 1 Interleukin-4
40 Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer Completed NCT00039052 Phase 1
41 First in Human Study to Assess Safety of VIS649 in Healthy Subjects Recruiting NCT03719443 Phase 1
42 Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects Completed NCT00620230 Phase 1 NVP-VAK694;NVP-VAK694
43 A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults Completed NCT00000853 Phase 1
44 Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer Active, not recruiting NCT02496273 Phase 1
45 Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma Completed NCT00878995 Phase 1 Placebo Testosterone;Testosterone Enanthate 100 MG/ML
46 A Study of Parsaclisib in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) Recruiting NCT03314922 Phase 1 Parsaclisib
47 A Phase 1 Safety and Pharmacokinetics Study of AER 001 Administered as a Dry Powder in Asthmatic Subjects Completed NCT00785668 Phase 1 AER 001
48 Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis Recruiting NCT02665754 Phase 1 Rescue medication for allergic rhinitis
49 QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel Active, not recruiting NCT02559674 Phase 1
50 Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients Unknown status NCT02894606 Thymoglobulin Induction;Basiliximab Induction

Search NIH Clinical Center for B-Cell Growth Factor

Genetic Tests for B-Cell Growth Factor

Anatomical Context for B-Cell Growth Factor

MalaCards organs/tissues related to B-Cell Growth Factor:

42
B Cells, T Cells, Lung, Breast, Liver, Bone, Kidney

Publications for B-Cell Growth Factor

Articles related to B-Cell Growth Factor:

(show top 50) (show all 169)
# Title Authors Year
1
Impact of the B Cell Growth Factor APRIL on the Qualitative and Immunological Characteristics of Atherosclerotic Plaques. ( 27820817 )
2016
2
Pillars article: Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J. Exp. Med. 1982. 155: 914-923. ( 23335802 )
2013
3
Molecular identification of IgE-dependent histamine-releasing factor as a B cell growth factor. ( 11359806 )
2001
4
Thioredoxin acts as a B cell growth factor in channel catfish. ( 11207242 )
2001
5
Effects of interleukin 3, interleukin 7, and B-cell growth factor on proliferation and drug resistance in vitro in childhood acute lymphoblastic leukemia. ( 10348147 )
1999
6
Increased production of B-cell growth factor by T lymphocytes in Graves' thyroid: possible role of CD4+ CD29+ cells. ( 9292944 )
1997
7
Complementary DNA for 12-kilodalton B cell growth factor: misassigned. ( 17759701 )
1996
8
Complementary DNA for 12-kilodalton B cell growth factor: misassigned. ( 17759700 )
1996
9
Complementary DNA for 12-kilodalton B cell growth factor: misassigned. ( 8928012 )
1996
10
Complementary DNA for 12-kilodalton B cell growth factor: misassigned. ( 8928011 )
1996
11
Response: complementary DNA for 12-kilodalton B cell growth factor: misassigned. ( 17759702 )
1996
12
Increased production of B cell growth factor (BCGF) in SjAPgren's syndrome. ( 8864831 )
1996
13
Identification of a cDNA for a human high molecular-weight B-cell growth factor. ( 8755619 )
1996
14
Expression and characterization of a B cell growth promoting polypeptide derived from the 12 kDa B cell growth factor gene (BCGF 1). ( 7698329 )
1995
15
[Production and role of B cell growth factor (BCGF) in SjAPgren's syndrome]. ( 8531348 )
1995
16
A combination of lipopolysaccharide and B-cell growth factor increases lymphocyte metaphase yields in B-cell chronic leukemia. ( 8500104 )
1993
17
Identification of a cDNA for a human high-molecular-weight B-cell growth factor. ( 8327514 )
1993
18
Human low molecular weight B cell growth factor induces surface IgM+/A- B cells to express and secrete IgA. ( 1506692 )
1992
19
Low-molecular weight B cell growth factor (BCGF-12KD) as an autocrine growth factor in B cell chronic lymphocytic leukemia. ( 1623931 )
1992
20
Abnormal production of B cell growth factor in patients with systemic lupus erythematosus. ( 1628424 )
1992
21
The rapid development of a fatal, disseminated B cell lymphoma following liver transplantation--serial changes in levels of soluble serum interleukin 2 and interleukin 4 (B cell growth factor). ( 1585481 )
1992
22
Human interleukin 7 is a B cell growth factor for activated B cells. ( 1826263 )
1991
23
Abnormal response to a human B cell growth factor in patients with common variable immunodeficiency (CVI). ( 1646248 )
1991
24
Tumor necrosis factor-alpha and B-cell growth factor induce leukemic hairy cells to proliferate in vitro. ( 1751949 )
1991
25
Low MW B-cell growth factor potentiates histamine release from human basophil leucocytes. ( 2071166 )
1991
26
Hyperphosphorylation of CD20 in hairy cells. Alteration by low molecular weight B cell growth factor and IFN-alpha. ( 1703183 )
1991
27
Intracellular signaling events associated with the induction of proliferation of normal human B lymphocytes by two different antigenically related human B cell growth factors (high molecular weight B cell growth factor (HMW-BCGF) and the complement factor Bb). ( 1847385 )
1991
28
Induction of proliferation by high molecular weight B cell growth factor or low molecular weight B cell growth factor is associated with increases in intracellular calcium in different subpopulations of human B lymphocytes. ( 2021972 )
1991
29
Characterization of B cell growth in systemic lupus erythematosus. Effects of recombinant 12-kDa B cell growth factor, interleukin 4 and transforming growth factor-beta. ( 2253682 )
1990
30
Differential response of malignant human B-cells to anti-IgM immunoglobulin (anti-mu) and B-cell growth factor: unique direct cytotoxicity of anti-mu on prolymphocytic leukemia cells. ( 2119832 )
1990
31
Effect of a low-molecular-weight B cell growth factor on the proliferation of normal and neoplastic lymphocytes in lymphomas. ( 2372778 )
1990
32
Functional studies examining the subpopulation of human B lymphocytes responding to high molecular weight B cell growth factor. ( 2258603 )
1990
33
Establishment and characterization of human B-cell lymphoma cell lines using B-cell growth factor. ( 2155676 )
1990
34
In vitro production of B cell growth factor and B cell differentiation factor by peripheral blood mononuclear cells and bronchoalveolar lavage T lymphocytes from patients with idiopathic pulmonary fibrosis. ( 2208788 )
1990
35
B-cell growth factor-induced and alpha-interferon-inhibited proliferation of hairy cells coincides with modulation of cell surface antigens. ( 2354460 )
1990
36
B8.7 antigen is present on B-cell precursor acute lymphocytic leukemia. Correlation with the low molecular weight B-cell growth factor responsiveness of these cells. ( 2137354 )
1990
37
Establishment of a human B cell line that responds specifically to B cell growth factor. ( 2243835 )
1990
38
Adrenocorticotropin (ACTH) functions as a late-acting B cell growth factor and synergizes with interleukin 5. ( 1964384 )
1990
39
Immortalization of Epstein-Barr virus-infected CD23-negative B lymphocytes by the addition of B cell growth factor. ( 2155999 )
1990
40
Effects of low molecular weight B-cell growth factor on proliferation of leukemic cells from children with B-cell precursor-acute lymphoblastic leukemia. ( 2302462 )
1990
41
Involvement of HLA Antigens, Interleukin 2 Receptor and B-Cell Growth Factor in Interferon Action in Hairy Cell Leukemia. ( 27456740 )
1990
42
Proliferation of B cells from chronic lymphocytic leukemia is selectively promoted by B cell growth factor. ( 2496557 )
1989
43
Human B cell growth factor enhances proliferation and glial fibrillary acidic protein gene expression in rat astrocytes. ( 2487687 )
1989
44
Structural homology of interferon-gamma with B-cell growth factor and its proliferative effect on long term B-cell lines. ( 2497278 )
1989
45
Cellular activation without proliferation to B cell growth factor and interleukin 2 in chronic lymphocytic leukaemia B cells stimulated with phorbol ester plus calcium ionophore. ( 2500274 )
1989
46
Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. ( 2522498 )
1989
47
Low molecular weight B cell growth factor-responsive cloned human B cell lines. I. Phenotypic differences and lack of requirement for CD23 (Fc epsilon RII). ( 2529311 )
1989
48
Negative modulation of Epstein-Barr virus episomes by a human B-cell growth factor. ( 2542626 )
1989
49
A monocyte-derived B cell growth factor is IFN-beta 2/BSF-2/IL-6. ( 2544130 )
1989
50
Potentiation of the proliferative response of human B lymphocytes to low molecular weight B cell growth factor (LMW-BCGF) by fibroblast growth factors (FGFs). ( 2548739 )
1989

Variations for B-Cell Growth Factor

Expression for B-Cell Growth Factor

Search GEO for disease gene expression data for B-Cell Growth Factor.

Pathways for B-Cell Growth Factor

Pathways related to B-Cell Growth Factor according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 IFNG IL3 IL4 IL6 IL7 TNFSF13
2
Show member pathways
13.42 IFNG IL3 IL4 IL6 IL7 TNFSF13
3
Show member pathways
13.29 IFNG IL3 IL4 IL6 IL7
4
Show member pathways
13.17 IL3 IL4 IL6 IL7 TNFSF13
5
Show member pathways
13.07 IL3 IL4 IL6 IL7 TNFSF13
6
Show member pathways
12.98 IFNG IL3 IL4 IL6 IL7 TNFSF13
7
Show member pathways
12.77 IL3 IL4 IL6 IL7
8
Show member pathways
12.65 IFNG IL3 IL4 IL6 TNFSF13
9 12.6 IFNG IL3 IL4 IL6 IL7
10
Show member pathways
12.4 IFNG IL4 IL6
11 12.37 IFNG IL3 IL4
12
Show member pathways
12.32 IFNG IL3 IL4
13
Show member pathways
12.24 IFNG IL4 IL6
14
Show member pathways
12.15 IFNG IL4 IL6
15
Show member pathways
12.15 IFNG IL4 IL6
16
Show member pathways
12.13 IFNG IL3 IL4 IL6 IL7
17
Show member pathways
12.07 IFNG IL3 IL4 IL6
18
Show member pathways
12.02 IFNG IL4 IL6
19
Show member pathways
11.89 IFNG IL4 IL6
20 11.84 IFNG IL4 IL6 TNFSF13
21
Show member pathways
11.84 IFNG IL3 IL4 IL6 IL7
22 11.79 IFNG IL3 IL6
23 11.73 IFNG IL3 IL6
24 11.71 IFNG IL6 TNFSF13
25 11.69 IL3 IL4 IL6 IL7
26 11.66 IFNG IL4 IL6
27 11.63 IFNG IL4 IL7
28
Show member pathways
11.59 IFNG IL3 IL4
29 11.55 IFNG IL4 IL6
30 11.5 IL4 IL6
31
Show member pathways
11.5 IFNG IL6
32 11.44 IFNG IL6
33 11.42 IFNG IL3 IL4 IL6 IL7
34 11.4 IFNG IL6
35 11.38 IL4 IL6
36 11.37 IFNG IL6
37 11.36 IL3 IL6
38 11.36 IL3 IL6
39 11.34 IFNG IL4
40 11.32 IFNG IL6
41 11.23 IFNG IL6
42 11.18 IFNG IL4
43 11.06 IFNG IL4
44 10.96 IFNG IL4 IL6 IL7
45 10.89 IL3 IL4 IL6 IL7 TNFSF13
46 10.8 IL3 IL4 IL6 IL7 TNFSF13
47 10.48 IFNG IL3 IL4 IL6 IL7

GO Terms for B-Cell Growth Factor

Cellular components related to B-Cell Growth Factor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 IFNG IL3 IL4 IL6 IL7 TNFSF13
2 extracellular region GO:0005576 9.17 IFNG IL3 IL4 IL6 IL7 TNFSF13

Biological processes related to B-Cell Growth Factor according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.72 IFNG IL3 IL6 IL7 TNFSF13
2 positive regulation of gene expression GO:0010628 9.69 IL6 IL4 IFNG
3 cytokine-mediated signaling pathway GO:0019221 9.65 IL3 IL4 IL6 IL7 TXLNA
4 humoral immune response GO:0006959 9.54 IFNG IL6 IL7
5 positive regulation of T cell proliferation GO:0042102 9.49 IL6 IL4
6 positive regulation of B cell proliferation GO:0030890 9.48 IL7 IL4
7 B cell activation GO:0042113 9.46 TXLNA IL4
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.46 IFNG IL3 IL4 IL6
9 positive regulation of T cell differentiation GO:0045582 9.43 IL7 IL4
10 immune response GO:0006955 9.43 IFNG IL3 IL4 IL6 IL7 TNFSF13
11 positive regulation of chemokine production GO:0032722 9.4 IL7 IL6
12 regulation of signaling receptor activity GO:0010469 9.17 IFNG IL3 IL4 IL6 IL7 TNFSF13

Molecular functions related to B-Cell Growth Factor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL3 IL4 IL6 IL7
2 cytokine activity GO:0005125 9.17 IFNG IL3 IL4 IL6 IL7 TNFSF13
3 cytokine receptor binding GO:0005126 9.16 IL7 IL4

Sources for B-Cell Growth Factor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....